Medical physics

Esaote North America awarded three-year contract agreement with Group Purchasing Organization MAGNET GROUP, offering members access to its full suite of Ultrasound and Dedicated MRI products and services

Tuesday, August 3, 2021 - 12:00pm

The new agreement provides MAGNET GROUP members full access to Esaote North America's comprehensive imaging portfolio and services.

Key Points: 
  • The new agreement provides MAGNET GROUP members full access to Esaote North America's comprehensive imaging portfolio and services.
  • Esaote North America is internationally recognized as a leader in providing superior Ultrasound solutions and Dedicated MRI systems.
  • MAGNET GROUP members can access Esaote North America's suite of products on the MAGNET GROUP website magnetgroup.com under the "Radiology" category.
  • MAGNET GROUP members choose from over 200 no-hassle GPO contracts without volume compliance or bundled services issues and never pay membership dues or fees.

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Tuesday, August 3, 2021 - 4:30am

Through this acquisition, Rigaku will expand its life sciences modality business globally by combining MILabs' multi-modality businesses, including PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment for animals, with Rigaku's original X-ray imaging business for animals.

Key Points: 
  • Through this acquisition, Rigaku will expand its life sciences modality business globally by combining MILabs' multi-modality businesses, including PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment for animals, with Rigaku's original X-ray imaging business for animals.
  • Through this acquisition, Rigaku aims to strengthen its pre-clinical imaging business within the life sciences field by incorporating MILabs' radiation imaging and optical imaging technologies, a new initiative for Rigaku, while simultaneously building its existing X-ray imaging business.
  • Rigaku believes that pre-clinical imaging will become increasingly important in the life sciences field.
  • Rigaku will actively enter the life science market and aim to develop this field as one of its core businesses by 2025.

KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy

Thursday, July 29, 2021 - 1:00pm

Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.

Key Points: 
  • Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
  • KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US.
  • Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.

Most Hospitals in The U.S. Plan to Buy an X-Ray System, Says Report

Friday, July 30, 2021 - 1:00pm

This can be both an opportunity and a concern for watchers of the X-ray imaging market, according to IMV's report.

Key Points: 
  • This can be both an opportunity and a concern for watchers of the X-ray imaging market, according to IMV's report.
  • Almost two thirds of the hospitals "Yes" and "Maybe" plan to acquire fixed x-ray systems (primarily DR) and/or DR detector retrofit kits for their main radiology department over the next three years.
  • The report breaks out whether the need is new systems outright, retrofit systems or both.
  • The report also breaks out what size hospital answered in what ways, and which manufacturers customers will buy from.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Wednesday, July 28, 2021 - 4:54pm

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Wednesday, July 28, 2021 - 4:47pm

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

neuro42 Announces the Closing of $6.5M Series A Round

Tuesday, July 27, 2021 - 5:00pm

neuro42 , the medical technology company leading the next evolution of MRI and robotics, today announced the close of a $6.5M Series A financing round.

Key Points: 
  • neuro42 , the medical technology company leading the next evolution of MRI and robotics, today announced the close of a $6.5M Series A financing round.
  • Zepp Health led the financing round and is joined by ShangBay Capital and prominent angel investors, Krishna R. Bhupal and Philip Dolan.
  • To date, the Company has raised $7.8M of which $1.3M was in an oversubscribed seed round that closed earlier this year.
  • neuro42, Inc. is a San Francisco, CA based medical technology company focused on diagnostic imaging and image guided surgical interventions of the brain.

Clinical Trial Imaging Market worth $1.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Tuesday, July 27, 2021 - 3:30pm

The services segment accounted for the largest share of the market, by product and service segment, in 2020

Key Points: 
  • The services segment accounted for the largest share of the market, by product and service segment, in 2020
    Based on product and service, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The major players operating in this clinical trial imaging market are ICON plc.
  • (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC.

Clinical Trial Imaging Market worth $1.4 billion by 2026 - Exclusive Report by MarketsandMarkets™

Tuesday, July 27, 2021 - 3:30pm

The services segment accounted for the largest share of the market, by product and service segment, in 2020

Key Points: 
  • The services segment accounted for the largest share of the market, by product and service segment, in 2020
    Based on product and service, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The major players operating in this clinical trial imaging market are ICON plc.
  • (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC.

SimonMed Imaging Enhances Patient Services, Saves Millions in Voice and SMS Costs and Enables Future Growth with CPaaS Solution from IntelePeer

Monday, July 26, 2021 - 1:00pm

We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.

Key Points: 
  • We selected IntelePeer for their impressive track record and expertise, says SimonMed CIO Duleep Wikramanayke.
  • The companys solutions not only improve processes but also help in keeping overhead as low as possible.
  • Before implementation, SimonMeds voice and data costs totaled approximately $5.4 million.
  • SimonMed Imaging is the largest physician owned outpatient radiology practice in the United States and specializes in all major medical fields of medical imaging.